On December 9, 2024, clinical-stage biopharmaceutical company Technoderma Medicines Inc. (hereinafter referred to as "Technoderma") officially announced that its topical ointment TDM-180935, a JAK1/Tyk2 dual-target inhibitor developed for atopic
On July 1, 2016, TechnoDerma announced the completion of a multi-million yuan Angel round of financing. The completion of financing marks the official launch of the startup company and its innovative small molecule drug discovery program for the treatment
